title: Drugs for dengue: a patent review (2010-2014).
abstract: BACKGROUND
  Almost half the global population is estimated to be at risk of contracting dengue infection. Of the 400 million infections estimated to occur annually, 4 million can be potentially life-threatening leading to vascular leakage and shock. The only treatment available to severe dengue patients is fluid replacement therapy and supportive care. A drug for treating dengue is an urgent need.
  
  
  METHODS
  This article endeavors to provide an overview of the experimental dengue drugs being developed around the world as reflected in the recent patent literature spanning the last few years (2010-2014).
  
  
  CONCLUSIONS
  Dengue drug development is essentially in its infancy and currently hobbled by multiple factors including a poor understanding of the molecular mechanism of severe disease and lack of reliable small animal model for preclinical drug evaluation. More intense R&D coupled to setting up product development partnerships to facilitate the efficient movement of a drug molecule from the laboratory to the clinic is needed to make antiviral therapy for dengue a reality in the coming future.
authors.affiliation: Birla Institute of Technology and Science Pilani, Department of Biological Sciences , Hyderabad Campus, Jawahar Nagar, Shameerpet Mandal, Ranga Reddy District, Hyderabad-500078 , India +91 40 66303631 ; +91 40 66303998 ; swaminathan@hyderabad.bits-pilani.ac.in , ssn225@gmail.com.
authors.forename: Hemalatha
authors.initials: H
authors.lastname: Beesetti
authors.forename: Navin
authors.initials: N
authors.lastname: Khanna
authors.forename: Sathyamangalam
authors.initials: S
authors.lastname: Swaminathan
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003715:Dengue / Q000188:drug therapy* / Q000821:virology; D003716:Dengue Virus / Q000187:drug effects; D006801:Humans; D010330:Patents as Topic
chemical_list: D000998:Antiviral Agents
keywords: NS3 protease inhibitor; dengue antiviral; entry blocker; herbal antiviral